Safety and efficacy of intravenous Colchicine in children with Familial Mediterranean Fever

Rotem Tal, Rotem Semo Oz, Gil Amarilyo*, Tal Eidlitz-Marcus, Ori Goldberg, Yoel Levinsky, Orit Peled, Liora Harel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Familial Mediterranean Fever (FMF), the most common monogenic inflammatory disease, is mainly treated by oral Colchicine. However, 5% of patients are considered non-responders and, therefore, candidates for biologic therapy. Intravenous (IV) Colchicine treatment has been shown to be effective and safe in adult patients. The objective of this study was to evaluate the safety of IV Colchicine for pediatric FMF patients in our hospital, refractory to oral Colchicine, by reviewing their medical records. Inclusion criteria were all patients with FMF who commenced treatment with IV Colchicine before the age of 18 years, and received at least 6 months of IV therapy. The patients completed questionnaires to assess the efficacy of the treatment. Between 2004 and 2017, 7 pediatric FMF patients receiving maximal oral Colchicine doses and deemed non-responders were treated with weekly IV Colchicine, including 38 cumulative patient years of follow-up data (a full blood count, renal and liver function tests). All patients were homozygous for the M694V genotype. Long-term follow-up showed normal laboratory results with no Colchicine-related hospital admissions or toxicity. Global health assessment and the number of disease-free days have significantly improved (P < 0.05). Prolonged IV Colchicine use is described in pediatric FMF patients for the first time, with an excellent safety profile in our population, and decrease in intensity and frequency of attacks. In the biological era, IV Colchicine, although not leading to complete remission, may be considered a second-line option in countries where anti-interleukin 1 blockers are not available, or as a third-line option in case of failure to respond to biologics.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalRheumatology International
Issue number1
StatePublished - 1 Jan 2020


  • Familial Mediterranean Fever (FMF)
  • Intravenous Colchicine


Dive into the research topics of 'Safety and efficacy of intravenous Colchicine in children with Familial Mediterranean Fever'. Together they form a unique fingerprint.

Cite this